a trained musculoskeletal radiologist. For each DECT, clinical and biochemical characteristics of each patient were collected retrospectively. Results: 22 patients (men 77%), mean age 62.5 years and mean BMI 28.4 kg/m 2 were included. Mean gout duration was 108.0±114.4 months, mean of last available serum uric acid level was 520±193 μmol/l, and 15 patients had at least one clinical tophus. Mean estimated glomerular filtration rate (MDRD formula) was 47±27 ml/min/1.73 m 2 . One patient was on hemodialysis and one had received kidney transplant. A total of 39 DECT has been performed: 28 of peripheral joints and 11 of the spine (9 lumbar, 1 sacroiliac and 1 cervical). Spinal DECT were done in 10 patients to explore recurrent inflammatory pain (n=3 lumbar, 1 cervical and 1 buttock) or mechanical back pain (n=2 lumbar). 4 spinal DECT were performed in asymptomatic patients with extended peripheral tophi. Spinal MSU crystal deposits were disclosed by DECT in 83% (5/6) and 25% (1/4) of symptomatic and asymptomatic patients, respectively. In all painful patients, MSU crystal deposition was considered as a likely explanation of spinal symptoms. MSU crystal depositions was identified in apophyseal joints (n=5), cervical intervertebral disc (n=1) and yellow or interspinous ligaments (n=4). All involved apophyseal joints were eroded (figure 1). No vertebral bone erosion was observed. Calcification of spinal tophus was observed in 4 patients. DECT identified peripheral deposits in 15/18 (83.3%) patients. In peripheral DECT, bone erosions were observed in 71.4% and joint effusion in 32.1% of DECT positive peripheral joints. MSU crystal depositions were observed in tendons, cartilages or synovial membranes in 82.1% of positive DECT joints and in soft tissues in 64.3% of positive patients. MSU crystal deposits were calcified in 7 cases.
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Conclusions: MSU crystal depositions at the spine are present in 60% of patients in this retrospective DECT study. DECT can represent a performing imaging procedure for their detection in symptomatic patients. Further studies are needed to assess the clinical utility of DECT of the spine in gout. Background: Numerous data in sub-Saharan Africa suggest that MTP1 is not the hallmark of gout (1-5). Objectives: We carried out this study with the aim to determine the joint most involved at the time of diagnosis of gout in Cameroon. Methods: We performed a cross-sectional study in all outpatients seen at the Rheumatology unit of the Douala General Hospital, Cameroon, between 2004 and 2014. We included patients with diagnosis of gout according to ACR criteria 1977. The main characteristics of gout at diagnosis were collected, particularly the joints involved. A p<0.05 was significant. Results: At the end of this study, 511 patients (415 men and 96 women) with the diagnosis of gout were included. The mean age was 55.9±10.8 years. Joint pain (n=508, 99.4%) was the leading reason for consultation at the time of diagnosis. The knees (n=300, 62.6%)), ankles (n=187, 39.0%) and MTP1 (n=128, 26.7%) were the most affected joints. Table 1 presents the frequency of the joints affected, comparing our results with those of the other African series. There was no difference between MTP1 and others joints location (particularly knees and ankles) according to age, sex, place of residence, duration of disease, uric acid level, and associated comorbidities (p>0.05). Conclusions: MTP1 is not the joint most involved at the time of diagnosis of gout in sub-Saharan Africa. Diagnosis of gout should be considered before any inflammatory knee and ankle pain in patients from sub-Saharan Africa. Genetic studies would provide a better understanding of this feature. 
